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Abstract Body size, particularly large, is a matter of con-
cern among the lay public. Whether this is justified depends
upon the state of health and should be judged individually.
For patients with established chronic disease, there is suffi-
cient evidence to support the benefits of large body size, i.e.,
the obesity paradox. This uniform finding is shared over a
variety of cardiovascular, pulmonary, and renal diseases and
is counterintuitive to the current concepts on ideal body
weight. The scientific community has to increase the aware-
ness about differences for optimal body size in health and
disease. Simultaneously, clinicians have to be aware about
body weight dynamics implications and should interpret the
changes in the context of an underlying disease in order to
implement the best available management.
1 Perception of body size throughout history
Life expectancy and survival throughout mankind’sh i s t o r y
was and remains dependent upon ability to cope with harmful
stimuli. The human body itself developed very sophisticated
defense mechanisms, which, however, are primarily based on
rather primitive responses like inflammation, neurohormonal,
and sympathetic nervous system activation. Vital for all pro-
cesses is energy, which is derived from fat, proteins, and
carbohydrates. Energetic efficacy of life organisms, although
highest known in nature, is about 30% while the rest is lost
primarily through heat production. Chronic food shortage and
malnutrition have been the scourge of humankind throughout
history. This has led to development of safety measures to
accumulate energy when available to bridge over times of
need. As a matter of fact, an evolutionarily conserved gene
family important for fat depots, which store twice the amount
of energy as carbohydrates or proteins, have recently been
identified [1]. Until about a century or two ago, this gene
family served its purposes for the majority of the world’s
population. Nowadays, when abundant food is available all
over the year, activation may be prolonged to lead to signifi-
cant increase of body weight. It is therefore not surprising that
attitudesofhumankindtowardsbodysizechangedthroughout
centuries. Until recently, large body size reflected wealth and
wellbeing, and it was reserved for very few in the community
or population. Nowadays, the other extreme is preferred and
people are willing to deliberately reshape their body primarily
M. Lainscak (*)
Division of Cardiology,
University Clinic of Pulmonary and Allergic Diseases Golnik,
Golnik 36,
SI-4204 Golnik, Slovenia
e-mail: mitja.lainscak@guest.arnes.si
M. Lainscak: S. von Haehling:S. D. Anker
Applied Cachexia Research, Department of Cardiology,
Charité Medical School, Campus Virchow-Klinikum,
Berlin, Germany
S. von Haehling
Center for Cardiovascular Research (CCR),
Charité Medical School, Campus Mitte,
Berlin, Germany
W. Doehner
Center for Stroke Research, Berlin, Charite Medical School,
Berlin, Germany
S. D. Anker
Center for Clinical and Basic Research, IRCCS San Raffaele,
Rome, Italy
J Cachexia Sarcopenia Muscle (2012) 3:1–4
DOI 10.1007/s13539-012-0059-5due to aesthetic impulses, and less often due to health con-
cerns. Interesting in this context are differences between reli-
gions in their perception and presentation of goddesses: while
thin stature was associated with lack and suffering, large body
size with abundance and joy. Similar observations stem from
arts, literature, and medical opinion of the times, when corpu-
lence meant something good and desirable.
2 Obesity and Quetelet index
Obesity in lay public is usually associated with large bodysize.
For clinical practice and research purposes, reliable definitions
are needed but are not always available. The Quetelet index is
the ratio between body weightin kg and square of body height
in meters. It was first described by the Belgian polymath
Adolphe Quetelet during the course of developing “social
physics”,w h i c hw o u l dl i k e l yc o r r e s p o n dt oc u r r e n tu n d e r -
standing of epidemiology [2]. The current name, body mass
index (BMI), dates to 1972, when it was used as an estimation
of body fat [3]. Thereafter, it was adopted for use in daily
practiceandalsobytheWorldHealthOrganization.According
to its current definition, people with BMI <18.5 kg/m
2 are
considered underweight while those with BMI over 30 and
40 kg/m
2 are obese and morbidly obese, respectively. These
ranges are based on healthy populations and are valid only as
statistical categories, a fact that is largely being ignored. Inter-
national variations exist and some adjustments are needed for
specific populations [4].
3 Body size in health and disease: bad gone good
or obesity paradox
Only with sufficient and accessiblefood,together with modern
way of life and little or no physical activity, obesity increased
in prevalence to reach epidemic proportions [5]. Obesity is
today considered as a chronic disease and is listed in the
International Classification of Disease (ICD-9: E66.9). It is
linked with increased mortality, primarily through develop-
ment of cardiovascular disease [6]. Consequently, people are
much more worried by weight gain than weight loss, and
dieting is frequently used to obtain a “healthy weight”. Epide-
miological studies, however, have demonstrated that aging
attenuates association between high BMI and increased risk
of death [7]. In contrast to common public beliefs and guide-
lines for primary preventive medicine, high BMI confers pro-
tective effects for patients with established chronic diseases.
Although this seemingly paradoxical message penetrates the
public opinion only slowly, evidence is starting to accumulate.
About a decade ago, the first publication using “obesity para-
dox” in the article title was published [8]. A PubMed search of
February 6th, 2012 identified 96 publications that have used
the exact phrase in their title, and 138 used both words in any
combination (Fig. 1). Most studies used BMI to evaluate body
size in relation to all-cause mortality. The message derived
from small- to large-scale studies is uniform and suggests that
an optimal BMI with lowest risk of death is in the overweight
or even obese category. Table 1 summarizes some of the most
important publications about the obesity paradox in chronic
cardiovascular, pulmonary, and kidney disease as well as in
intensive carepatients[9–19]. In arecent study, the presence of
an obesity paradox has beenobservedin patients with diabetes
mellitus plus cardiovascular comorbidity [19]. The latter study
in particular provides evidence in contrast to common thinking
and to current guideline recommendations. Notably, these
recommendations are commonly based on mere translation
from primary prevention data and may not be applicable in
patient populations with established chronic diseases. We be-
lieve that an intellectual exercise recently performed for heart
failure [20] is valid for many chronic diseases. Rather than
merely repeating it over a plethora of conditions, we should
bring the current knowledge and experience to a next level.
While the relevant clinical question of weight management in
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swered, we certainly should tailor our management individu-
ally. Generally, non-edematous and particularly non-voluntary
weight loss should be recorded and managed aggressively. If
overlooked or ignored, a vicious circle of body wasting and
eventually cachexia may ensue [21]. Even obese patients are
vulnerable for such scenario, which is yet another obesity
paradox to be explored in the currently ongoing Studies Inves-
tigating Co-morbidities Aggravating Heart Failure (SICA-HF)
[22].Inreal life,nothingiscoincidentalandyoualwaysreacha
pay-off stage. Obesity-induced symptoms or syndromes like
sleep-disordered breathing in heart failure [23, 24] obviously
drive the trade-off between weight loss and obesity paradox
and are yet another example of balancing in clinical practice.
And this is where the long forgotten and neglected art of
medicine should be revived [25]; to help us balance between
thin and obese, between health and disease and the other way
around.
Table 1 Large-scale studies about obesity paradox in chronic disease
Condition and study/country N (% men) Age Main finding
Heart failure
Acute 108,927
(49%)
72±14 years Inhospital mortality decreased from 5.0% to 2.2% per BMI
quartiles The mortality OR for obese, overweight, and
underweight vs healthy weight was 0.74 (95%
CI 0.68–0.81), 0.83 (95% CI 0.76–0.90), and 1.34
(95% CI 1.15–1.58), respectively
(ADHERE registry) [9]
Chronic 7,767 (75%) 64±11 years Higher BMI associated with lower mortality risk:
adjusted HR for all-cause death for obese or
overweight vs healthy weight patients was 0.81
(95% CI 0.72–0.92) and 0.88 (95% CI 0.80–0.96),
respectively
(USA) [10]
Coronary artery disease
Coronary artery disease
and hypertension
22,576 (NA) 66±10 years With normal weight subjects as reference, overweight
and obese patients had better (HR 0.52–0.66, p<0.001)
and thin patients had worse survival (HR 1.85, p<0.001) (INVEST) [11]
Percutaneous coronary intervention 4,880 (70%) Median age 62 years Patients with BMI 27.5–30 kg/m
2 had lowest adjusted
HR for death (0.59, 95% CI 0.39–0.90) (Germany) [12]
Coronary artery bypass grafting 22,599 (72%) 63±10 years Lowest RR for 30-day mortality in patients with BMI
of 33 kg/m
2, patients with BMI<22 kg/m
2 had
significantly higher RR for death
(Germany) [13]
Stroke 2,785 (62%) Mean age 70 years Obese and overweight patients had significantly higher
early (1 week and 1 month) and long-term (10 years)
survival when compared to patients with normal BMI
(p<0.001 for all)
(Greece) [14]
Intensive care unit 9,935 (64%) 63±15 years Overweight (HR 0.86, 95% CI 0.74–0.99) and obese
(HR 0.83, 95% CI 0.69–0.99) patients had lower
60-day inhospital mortality.
(Germany) [15]
Chronic obstructive pulmonary disease
Acute exacerbation 968 (72%) 70±9 years In an adjusted model, BMI per 1 kg/m
2 unit increase
was associated with 5% less chance of death (hazard
ratio 0.95, 95% confidence interval 0.93–0.97)
(Slovenia) [16]
Stable disease 2,132 (57%) 56±11 years Adjusted RR for death in underweight vs normal
weight patients was 1.64 (95% CI 1.20–2.23) in men
and 1.42 (95% CI 1.07–1.89) in women
(Copenhagen city heart study) [17]
Chronic kidney disease 121,762
(54%)
63±15 years Higher BMI (optimal range 40–45) was independently
associated with better survival after adjustment for
available surrogates of nutritional status and
inflammation
(DaVita dialysis facilities, USA)
[18]
Diabetes plus cardiovascular disease 5,202 (66) 62±7 years Higher BMI (optimum range 30–35 kg/m
2) was
associated with lower mortality and hospitalization.
Weight loss but not weight gain was predictive
of increased mortality.
PROactive Study [19]
BMI body mass index, OR odds ratio, HR hazard ratio; RR relative risk; 95% CI 95% confidence interval
J Cachexia Sarcopenia Muscle (2012) 3:1–4 34 Clinical implications
BMI is an easily accessible parameter that carries important
information for patient risk stratification, and the so-called
obesity paradox relates to beneficial effects of large body size
in terms of mortality. The risks and benefits of overweight or
obese BMI categories in healthy individuals and chronic
disease patients, however, is diametrically different, and, thus,
public and also medical healthcare providers’ perception has
to be modified accordingly.
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